Global Lactulose Syrup Market Size By Type (Chemical Synthesis, Enzymatic Method), By Application (Pharmaceuticals, Food), By Region, And Segment Forecasts, 2023 to 2032

The Global Lactulose Syrup Market was valued at USD 210.4 million in 2023 and is projected to reach USD 348.7 million by 2031, growing at a CAGR of 6.7% during the forecast period from 2023 to 2031. Lactulose syrup, a synthetic disaccharide, is widely used for treating constipation and hepatic encephalopathy. The increasing prevalence of gastrointestinal disorders and rising awareness about digestive health are major drivers fueling the demand. Additionally, the aging global population and the preference for non-invasive treatments support market growth across both developed and developing regions.

Drivers:

1. Growing Prevalence of Chronic Constipation and Liver Diseases

Chronic constipation affects millions globally, particularly the elderly, and lactulose syrup is a frontline therapy. Moreover, its proven efficacy in treating hepatic encephalopathy in cirrhotic patients makes it indispensable in hepatology.

2. Aging Population and Rise in Geriatric Healthcare Needs

Older adults are more prone to gastrointestinal issues. With rising global life expectancy, the demand for safe and effective treatments like lactulose syrup continues to rise.

3. Increased Awareness and Availability of OTC Products

Consumer preference for over-the-counter (OTC) laxatives and increased awareness around gut health are contributing to greater adoption of lactulose syrup.

Restraints:

1. Availability of Alternative Therapies

The presence of other laxatives, such as polyethylene glycol and stimulant-based options, offers alternatives to lactulose and may inhibit its market expansion.

2. Side Effects and Compliance Issues

Bloating, gas, and abdominal discomfort are common side effects that can reduce patient compliance, especially with long-term use.

Opportunity:

1. Expansion in Emerging Healthcare Markets

Rising healthcare expenditure and growing awareness in Asia-Pacific and Latin America provide growth opportunities, especially as these regions improve access to gastroenterological treatments.

2. Product Innovation and Combination Therapies

New formulations, such as flavored or lower-dose variants and combination therapies with probiotics, are enhancing user compliance and creating differentiation in the market.

Market by System Type Insights:

Oral Syrup Segment Dominates

In 2023, the oral syrup format remained the largest and most preferred segment due to ease of administration, especially for pediatric and geriatric patients. Its quick onset of action and convenience contribute to its dominance.

Powder and Sachets Segment to Witness Notable Growth

While still emerging, powder formulations and sachets are gaining popularity due to portability and extended shelf life, especially in institutional and rural settings.

Market by End-use Insights:

Hospitals Remain Primary Consumers

Hospitals accounted for the largest share in 2023 due to widespread prescription-based usage for inpatients with hepatic encephalopathy or severe constipation.

Retail Pharmacies and Online Platforms to See Strong Growth

Retail and online pharmacy segments are experiencing increased traction as awareness grows among end users, and self-medication trends continue to rise in urban regions.

Market by Regional Insights:

North America Leads Globally

North America dominated the market in 2023, driven by high diagnosis rates, advanced healthcare infrastructure, and strong consumer awareness.

Asia-Pacific to Be the Fastest-Growing Region

Rapid urbanization, expanding healthcare access, and an aging population make Asia-Pacific the most lucrative region for future growth, especially in India, China, and Japan.

Competitive Scenario:

Key players in the Global Lactulose Syrup Market include Abbott Laboratories, Fresenius Kabi, Morinaga Milk Industry Co., Ltd., Bausch Health Companies Inc., Solvay, Hikma Pharmaceuticals, and LEO Pharma A/S. These companies focus on product diversification, geographic expansion, and strategic partnerships.

Key Developments:

In 2023, Abbott launched a sugar-free lactulose variant tailored for diabetic and weight-conscious consumers.

Fresenius Kabi expanded its lactulose production facility in Germany in 2024 to meet rising demand across Europe and Asia.

In 2025, Bausch Health introduced a new lactulose formulation with improved palatability, targeting pediatric usage.

Scope of Work – Global Lactulose Syrup Market

FAQs:

1. What is the current market size of the Global Lactulose Syrup Market?

The market size was valued at USD 210.4 million in 2023.

2. What is the major growth driver of the Global Lactulose Syrup Market?

The primary growth driver is the increasing prevalence of constipation and liver-related disorders, especially among the elderly.

3. Which is the largest region during the forecast period in the Global Lactulose Syrup Market?

North America holds the largest market share, driven by advanced healthcare systems and strong product availability.

4. Which segment accounted for the largest market share in the Global Lactulose Syrup Market?

The Oral Syrup segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Lactulose Syrup Market?

Abbott Laboratories, Fresenius Kabi, Bausch Health Companies Inc., Hikma Pharmaceuticals, Morinaga Milk Industry Co., and LEO Pharma A/S are among the major players.